# Treatment of Cabotamig (ARB202) in Advanced Gastrointestinal Cancer Patients

> **NCT05411133** · PHASE1 · COMPLETED · sponsor: **Arbele Pty Ltd** · enrollment: 33 (actual)

## Conditions studied

- Gastrointestinal Cancer
- Cholangiocarcinoma
- Liver Cancer
- Colorectal Adenocarcinoma
- Pancreatic Cancer
- Gastric Cancer
- Esophageal Adenocarcinoma
- Gastroesophageal Junction
- Gastrointestinal Neuroendocrine Tumors

## Interventions

- **DRUG:** Cabotamig (ARB202)

## Key facts

- **NCT ID:** NCT05411133
- **Lead sponsor:** Arbele Pty Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-05-30
- **Primary completion:** 2025-07-23
- **Final completion:** 2025-07-23
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2026-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05411133

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05411133, "Treatment of Cabotamig (ARB202) in Advanced Gastrointestinal Cancer Patients". Retrieved via AI Analytics 2026-07-24 from https://api.ai-analytics.org/clinical/NCT05411133. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*